（文章来源：证券日报） 证券日报网讯 12月18日晚间，吉贝尔发布公告称，公司于近日收到1项国家知识产权局颁发的发明专利 证书，专利名称为"一种紫杉烷衍生物及其制备方法、应用"。 ...

该发明专利的取得是公司核心技术的体现和延伸，本次发明专利的获得不会 对公司近期经营产生重大影响，但有利于进一步完善公司知识产权保护体系，发 挥自主知识产权的技术优势，促进技术创新，从而提升公司核心竞争力。 特此公告。 江苏吉贝尔药业股份有限公司董事会 2025 年 12 月 19 日 1 证券代码：688566 证券简称：吉贝尔 公告编号：2025-050 江苏吉贝尔药业股份有限公司 关于获得发明专利的自愿性披露公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏吉贝尔药业股份有限公司（以下简称"公司"）于近日收到 1 项国家知 识产权局颁发的发明专利证书，具体如下： | 发明专利 | 专利号 | 专利 | 授权 | 专利权人 | 专利 | | | --- | --- | --- | --- | --- | --- | --- | | 名称 | | 申请日 | 公告日 | | 期限 | | | | | | | | 20 | 年 | | 一种紫杉烷衍生 | ZL 2023 1 | | | 江苏吉贝尔 | （ | 自 | ...

该发明专利的取得是公司核心技术的体现和延伸，本次发明专利的获得不会对公司近期经营产生重大影 响，但有利于进一步完善公司知识产权保护体系，发挥自主知识产权的技术优势，促进技术创新，从而 提升公司核心竞争力。 格隆汇12月18日丨吉贝尔(688566.SH)公布,公司于近日收到1项国家知识产权局颁发的发明专利证书。发 明专利名称：一种紫杉烷衍生物及其制备方法、应用，专利号：ZL 2023 1 1469030.2。 上述发明属于药物化学领域，具体涉及一种紫杉烷衍生物及其制备方法和应用。该发明提供的化合物可 用于紫杉烷类抗癌化合物的杂质的检测，能够为紫杉烷类抗癌化合物的质量控制提供对照品；控制本发 明提供的紫杉烷衍生物含量能够明显改善降低紫杉烷类抗癌化合物作为药物应用时的毒性或副作用以及 改善其长期稳定性，并对提高紫杉烷衍生物作为药物应用时的药理活性有明显益处。 ...

上述发明属于药物化学领域，具体涉及一种紫杉烷衍生物及其制备方法和应用。该发明提供的化合物可 用于紫杉烷类抗癌化合物的杂质的检测，能够为紫杉烷类抗癌化合物的质量控制提供对照品；控制本发 明提供的紫杉烷衍生物含量能够明显改善降低紫杉烷类抗癌化合物作为药物应用时的毒性或副作用以及 改善其长期稳定性，并对提高紫杉烷衍生物作为药物应用时的药理活性有明显益处。 该发明专利的取得是公司核心技术的体现和延伸，本次发明专利的获得不会对公司近期经营产生重大影 响，但有利于进一步完善公司知识产权保护体系，发挥自主知识产权的技术优势，促进技术创新，从而 提升公司核心竞争力。 格隆汇12月18日丨吉贝尔(688566.SH)公布,公司于近日收到1项国家知识产权局颁发的发明专利证书。发 明专利名称：一种紫杉烷衍生物及其制备方法、应用，专利号：ZL 2023 1 1469030.2。 ...

吉贝尔公告称，近日收到国家知识产权局颁发的发明专利证书，专利名称为"一种紫杉烷衍生物及其制 备方法、应用"，专利号为 ZL202311469030.2，申请日为 2023 年 11 月 7 日，授权公告日为 2025 年 12 月 16 日，专利权人为公司，专利期限 20 年。该发明可用于紫杉烷类抗癌化合物杂质检测，利于质量控 制。本次获专利不会对近期经营产生重大影响，但有助于完善知识产权保护体系，提升竞争力。 ...

（文章来源：证券日报） 证券日报网讯 12月11日，吉贝尔在互动平台回答投资者提问时表示，截至2025年12月10日收市，公司 股东总数为7087户。 ...

Core Insights - The company, Jibeier, reported that as of October 31, 2025, the total number of shareholders is expected to be 7,763 [2] Summary by Category - **Company Information** - Jibeier has communicated to investors that the total number of shareholders will reach 7,763 by the end of October 2025 [2]

Core Viewpoint - The stock of Jibeier has experienced a decline recently despite a year-to-date increase, indicating potential volatility in its market performance [2]. Group 1: Stock Performance - As of November 19, Jibeier's stock price decreased by 2.00%, trading at 29.33 CNY per share with a total market capitalization of 5.849 billion CNY [1]. - Year-to-date, Jibeier's stock has risen by 34.05%, but it has seen a decline of 5.99% over the last five trading days, 8.00% over the last 20 days, and 21.28% over the last 60 days [2]. Group 2: Company Overview - Jibeier Pharmaceutical Co., Ltd. was established on November 13, 2001, and went public on May 18, 2020. The company specializes in the research, production, and sales of pharmaceuticals [2]. - The main revenue sources for Jibeier include Likujun tablets (72.72%), Nigulol tablets (14.20%), Yipingfeng capsules (4.88%), and others [2]. Group 3: Financial Performance - For the period from January to September 2025, Jibeier reported a revenue of 704 million CNY, reflecting a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase year-on-year [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million CNY in dividends, with 252 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, Jibeier had 7,742 shareholders, an increase of 28.97% from the previous period, with an average of 25,759 circulating shares per shareholder, a decrease of 22.46% [2]. - Notable new institutional shareholders include Caitong Advantage Industry Rotation Mixed Fund and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3].

Core Viewpoint - The company, Jibeier (688566), is focusing on expanding its market presence and product sales, particularly in underdeveloped regions, while also advancing its new drug development efforts, including an antidepressant and an oncology drug. Sales Strategy and Market Development - The company acknowledges significant sales disparities across regions and is implementing strategies to enhance sales in underperforming areas, aiming for regions like South and Central China to reach 80% of East China's sales levels [2] - The company has established a dedicated division and expert network to promote its hypertension drug, Niqunluo Tablets, which has shown strong sales growth, with over 7,000 hospitals covered as of September 2025, and an increase of 2,500 hospitals in the past year [2][11] Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 704 million yuan, a year-on-year increase of 9.52%, and a net profit of 197 million yuan, up 12.8% [16] - In Q3 2025, the company achieved a single-quarter revenue of 249.5 million yuan, a 19.08% increase year-on-year, driven by sales growth in its core products [10][16] New Drug Development - The company is preparing to submit the application for its antidepressant drug JJH201501, which has completed Phase III clinical trials and demonstrated efficacy comparable to existing treatments [6][14] - The oncology drug JJH201601 is currently in Phase IIa trials, focusing on cholangiocarcinoma patients, with plans for further clinical trials in advanced head and neck cancers [9] Future Development Strategy - The company plans to leverage its product and technological advantages to expand the sales scale of key products like Likujun Tablets and Niqunluo Tablets, while also accelerating new drug development [7] - The company aims to enhance communication with the secondary market to improve its stock performance, despite recent underperformance [5]

Core Viewpoint - The company is actively preparing the application materials for the new drug JJH201501 and is progressing with the subsequent processes while ensuring compliance with information disclosure obligations [1] Group 1 - The company is responding to investor inquiries regarding the status of the new drug application [1] - The company will disclose relevant information in accordance with regulations through designated media [1]